Romiplostim

Evidence Level: L5

Predicted Indications: 10

Romiplostim

Pharmacist Assessment Report

Romiplostim: Primary release disorder of platelets

One-Sentence Summary

Romiplostim is a thrombopoietin receptor (MPL) agonist, originally used for autoimmune (immune) thrombocytopenia. The TxGNN model predicts it may be effective for primary release disorder of platelets, but there are currently 0 clinical trials and only 1 indirect publication supporting this direction. The mechanistic rationale is weak, because release disorders are defects of platelet function rather than platelet number.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	Primary release disorder of platelets
TxGNN Prediction Score	1.0000
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 2 of 2)
Number of DINs	2 (marketed: 2)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the compiled data. From general pharmacology, romiplostim is a peptide agonist of the thrombopoietin receptor (MPL). It stimulates megakaryocyte proliferation and platelet production, and it is used to raise platelet counts in chronic immune thrombocytopenia (ITP).

The prediction is hard to justify mechanistically. Primary release disorders are qualitative platelet defects in granule secretion, and platelet counts are usually normal. Raising platelet number is not expected to correct defective secretion. The only linked paper (PMID 25682608) studies autoantibody inhibition of proplatelet formation in ITP, not release disorders, so it gives only indirect context. The very high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.

Other predicted indications (for context)

Rank	Predicted Indication	TxGNN Score	Evidence Level	Assessment
2	Pseudo-von Willebrand disease	1.0000	L5	Platelet GPIb gain-of-function defect. TPO agonism may increase hyper-reactive platelets. No evidence.
3	Glanzmann thrombasthenia	1.0000	L5	Qualitative defect with normal counts. Weak rationale.
4	Fetal and neonatal alloimmune thrombocytopenia	0.9999	L5	Most plausible candidate. Immune-mediated platelet destruction resembles ITP, but only indirect evidence exists.
5	Scott syndrome	0.9997	L5	Defect in phosphatidylserine exposure. TPO agonism does not address it.
6	Hemorrhagic disorder due to constitutional thrombocytopenia	0.9995	L5	Plausible for some subtypes only. Subtype-specific evidence is needed.
7	Bleeding diathesis due to collagen receptor defect	0.9995	L5	Receptor signalling defect. Not corrected by higher platelet counts.
8	Platelet-type bleeding disorder	0.9993	L5	Broad, mostly qualitative category. Limited relevance.
9	Autosomal dominant macrothrombocytopenia	0.9988	L5	Conceivable, but bleeding is usually mild and the defect is often downstream of TPO signalling.
10	Ehlers-Danlos syndrome, fibronectinemic type	0.9985	L5	No clear link to the TPO/MPL pathway.

Among these, fetal and neonatal alloimmune thrombocytopenia (FNAIT) has the most supporting literature, although it is still indirect.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

For the top-ranked indication (primary release disorder of platelets):

PMID	Year	Type	Journal	Key Findings
25682608	2015	Basic/mechanistic study	Haematologica	Antiplatelet autoantibodies from ITP patients inhibit proplatelet formation by megakaryocytes and impair platelet production in vitro. This concerns ITP, not release disorders.

For the best-supported alternative (FNAIT), all of the following are indirect:

PMID	Year	Type	Journal	Key Findings
31239245	2019	Review	Blood Advances	Romiplostim in paediatric ITP: drug development and current practice. FDA approval extended to children ≥1 year in December 2018.
34711622	2021	Case report	BMJ Case Reports	Management of refractory ITP in pregnancy.
23257464	2012	Review	Zhongguo Shi Yan Xue Ye Xue Za Zhi	Review of thrombopoietic drugs for childhood chronic and refractory ITP.
27605856	2016	Case report	Asian J Transfus Sci	Refractory ITP in pregnancy managed with eltrombopag (a different TPO mimetic).
20410910	2010	Review/Perspective	J Perinatol	Whether novel thrombopoietic agents could reduce platelet transfusions in neonates.
23822831	2013	Case report	Eur J Haematol	Complete remission of refractory ITP after a short course of romiplostim.

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02322854	NPLATE	Not specified	Not specified
02322862	NPLATE	Not specified	Not specified

Safety Considerations

Drug Interactions: A Major interaction with carfilzomib is recorded (DDInter). Romiplostim’s pharmacology entry also confirms its target is the thrombopoietin receptor (MPL).
Theoretical concerns for predicted indications: In pseudo-von Willebrand disease, raising the number of hyper-reactive platelets is a theoretical risk. Placental transfer and fetal/neonatal safety of romiplostim are unestablished for FNAIT.

Please refer to the package insert for warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The top prediction rests on a computational score alone. There are no trials, and the single linked paper concerns ITP rather than release disorders. Romiplostim raises platelet counts but would not be expected to correct a qualitative secretion defect.

To proceed, the following is needed:

Health Canada package insert warnings and contraindications (blocking for safety screening)
Mechanism of action data
Approved indication text and dosage forms for the Canadian licences
Direct evidence in the predicted indication. If the team wishes to pursue a lead, FNAIT or selected inherited thrombocytopenia subtypes are more plausible than release disorders. Those would need targeted literature review and fetal/neonatal safety data.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.